XFOR•benzinga•
X4 Pharmaceuticals Secures Licensing Deal With Norgine To Bring Mavorixafor To Europe, Australia, And New Zealand; Total Deal Value Could Exceed €254M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga